What Available Research Shows

The Cochrane Collaboration is an independent group of researchers who don’t sell anything — no vaccines, no drugs. Their entire job is to dig through the research and tell it straight. So when they did their biggest review of flu vaccines in healthy adults, (80,000 people, 52 studies, last updated in 2018) I paid attention. (5)

Here’s what they found:

• The benefit is real, but small. Picture 71 vaccinated adults: the shot prevents the flu in about one of them
• It barely moved the needle on missed workdays or hospitalizations
• Cochrane also noted that much of the underlying research was weak, marked by poorly designed studies and heavy industry funding

It’s not Cochrane’s job to hand out recommendations, but they were blunt that the evidence doesn’t back the confident, everyone-needs-one push we hear every fall. This isn’t an argument that influenza is harmless or that vaccination is pointless. If you’re older, immunocompromised, or managing chronic illness, the math looks different for you. It’s an argument that for the healthy majority, the data doesn’t support the certainty in the pitch.

None of this means a small benefit isn’t worth having. If the risk were truly zero, a 1-in-71 reduction is still a reduction, for you and potentially for the people around you. Flu vaccines are a bit unusual, though: they’re what researchers call “leaky,” meaning they lower your odds of getting sick, but they don’t reliably stop transmission. So the herd-immunity case for influenza vaccination is weaker than people assume. Either way, that whole calculation rests on one assumption: that the risk really is zero. That’s exactly where the new mRNA product gets complicated.

The Effectiveness Number You’ve Heard Before

You’ll hear the flu shot’s effectiveness quoted as 40-60%. (4) That number is real, but not as impressive as it might sound. It’s measuring a cut to a risk that was already fairly low to begin with, not a cut to something big. And in years when the vaccine doesn’t match the strain that’s actually circulating, even that modest number drops further. This is the standard flu shot most of us have gotten for years. It’s also the shot the new mRNA vaccine gets compared against.

Why an Annual Shot May Work Against You Over Time

There’s a deeper concern with a shot you take every year. Immunologists have long understood something called immune imprinting: your immune system tends to lock onto the first version of a virus it encounters, and can respond less well to later versions once the virus has changed. This is well-established flu science and there’s published evidence that getting a flu vaccine year after year can actually blunt its effectiveness over time. (6, 8, 2)

Introducing mRNA Vaccines

Traditional vaccines usually inject a small, weakened, or inactivated piece of a virus so your immune system can learn to recognize it, but mRNA vaccines don’t contain any virus at all. Instead, they deliver a set of instructions (mRNA) wrapped in a tiny fat bubble called a lipid nanoparticle like a recipe card mailed in an envelope. Once inside your cells, that recipe tells your own cells to temporarily build a single piece of the virus, usually a protein from its outer surface. If these instructions are received correctly, your immune system spots that protein, recognizes it as foreign, and builds antibodies and immune memory against it.

On August 5, 2026, the FDA approved the first mRNA flu vaccine, for adults 50 and older. The trial that got it approved followed nearly 41,000 adults across eleven different countries. (11)

Here’s what I found interesting about this trial:

• 2.0% of people who got the mRNA shot caught a confirmed case of flu, compared to 2.8% of people who got the standard shot. Both groups were vaccinated and the gap between them was less than one percentage point.
• It didn’t include a placebo or unvaccinated group, only a comparison against the standard flu shot.
• Its protection against H3N2, historically the roughest strain on people, was the weakest part of the results.

So headlines calling this the “first mRNA flu vaccine” make it sound like a leap forward. The trial shows something much smaller: a modest edge over a shot that wasn’t that impressive to begin with. And a small edge only matters if it doesn’t come with a new set of risks, which is worth looking at closely.

A Safety Window With a Hole In the Middle

Two things about how the trial was run deserve a closer look:

First: the myocarditis check was only 42 days. Myocarditis and pericarditis, inflammation of the heart muscle and its lining, were the signature serious injury of the COVID mRNA vaccines, concentrated in young males. In the flu trial, the active surveillance window for those exact injuries was a pre-specified 42 days. (11) No cases turned up in that window. After day 42, no one was looking. An injury that presents weeks to months out, or scars quietly and surfaces years later, fell outside the observation window.

Second: the trial only enrolled adults 50 and older. The one demographic where mRNA myocarditis clusters, young men roughly 16 to 29, wasn’t in the study at all. You can’t detect a signal in a group you never enrolled, and even the 50-and-older group here isn’t automatically in the clear.

So next time you hear this vaccine described as safe, it’s worth remembering what that’s built on: 42 days of watching, in an age group chosen to exclude the people historically most affected. That’s not a footnote. Leaving them out made the safety picture look cleaner than it might otherwise have looked, and made FDA approval easier to get. Furthermore, none of this guarantees the vaccine stays limited to adults 50 and older. Approvals like this tend to widen over time as more data comes in.

The Open Questions This Vaccine Inherits

The Influenza mRNA vaccine rides the same platform as the COVID mRNA vaccine, and thus inherits the same unresolved questions.

• It concentrates and keeps producing, instead of getting cleared. A traditional flu shot gives your immune system something already-made to inspect. Your body looks at it, mounts its response, and clears it out. The mRNA vaccines work differently: it may build up in certain organs and spread throughout your body where it turns your own cells into a production line to create more of those viral proteins I mentioned. We don’t yet know how long that process runs, and once it’s injected, there’s no way to stop it. (9, 3, 12)
• The delivery lipids are inflammatory in their own right, which is why the mRNA shot roughly doubled sore arms and body-wide reactions like fatigue, chills, or headache, compared to the standard vaccine. (11)
• Unknown effects of annual vaccination: After repeated COVID mRNA doses, some people’s antibodies shifted toward a “tolerant” type, the kind of low-key response your immune system usually reserves for things it’s decided aren’t worth fighting. What that shift would mean after years of annual flu shots is simply unstudied. (7)
• Manufacturing purity: Some scientists have raised concerns about manufacturing purity, specifically, tiny leftover fragments of DNA from the production process ending up in the final product. Regulators say the levels stay within safe limits, but other researchers question whether the testing catches everything it should. This is a genuine, ongoing disagreement, not something that’s been fully settled either way. (10, 1)

Most of these sit in the mainstream literature, not in the 30-second pharmacy pitch, and you certainly won’t hear it on the TV commercials.

The first of many

This is the first mRNA vaccine to reach the general, everyday adult market, outside of a pandemic emergency. And it won’t be the last. Vaccines for RSV, a combined COVID-flu shot, and even cancer vaccines are moving through development on the same platform. Whatever we accept as normal right now, short safety windows, comparing against a weak vaccine instead of no vaccine at all, leaving out the people most at risk, becomes the standard that the next ones are built on.

Here’s Where I Land

First off, does a healthy adult even need an annual flu shot? The benefit is already small; only about 1 in 71 people who get vaccinated are protected from a case of flu, and there’s evidence that getting vaccinated year after year may blunt the effectiveness over time. That said, if you’re older, immunocompromised, or managing serious chronic illness, the flu may be a bigger threat to you.

If you and your provider decide the answer is yes, here’s the honest comparison worth discussing. A standard flu shot is the option with the most safety history behind it. The newer mRNA version only beats that mediocre shot by less than a percentage point, roughly doubles your odds of a sore arm, carries a still-unfinished safety profile, and was never tested in the people most prone to its signature complication.

As always, ask questions, weigh the tradeoffs, and make the decision that best fits your health, not the calendar.

Blessings,
Dr. Jeff Davis